206 related articles for article (PubMed ID: 35115686)
1. Noncoding genetic variation in GATA3 increases acute lymphoblastic leukemia risk through local and global changes in chromatin conformation.
Yang H; Zhang H; Luan Y; Liu T; Yang W; Roberts KG; Qian MX; Zhang B; Yang W; Perez-Andreu V; Xu J; Iyyanki S; Kuang D; Stasiak LA; Reshmi SC; Gastier-Foster J; Smith C; Pui CH; Evans WE; Hunger SP; Platanias LC; Relling MV; Mullighan CG; Loh ML; Yue F; Yang JJ
Nat Genet; 2022 Feb; 54(2):170-179. PubMed ID: 35115686
[TBL] [Abstract][Full Text] [Related]
2. GATA3 germline variant is associated with CRLF2 expression and predicts outcome in pediatric B-cell precursor acute lymphoblastic leukemia.
Madzio J; Pastorczak A; Sedek L; Braun M; Taha J; Wypyszczak K; Trelinska J; Lejman M; Muszynska-Roslan K; Tomasik B; Derwich K; Koltan A; Kazanowska B; Irga-Jaworska N; Badowska W; Matysiak M; Kowalczyk J; Styczynski J; Fendler W; Szczepanski T; Mlynarski W
Genes Chromosomes Cancer; 2019 Sep; 58(9):619-626. PubMed ID: 30859636
[TBL] [Abstract][Full Text] [Related]
3. Inherited GATA3 variants are associated with Ph-like childhood acute lymphoblastic leukemia and risk of relapse.
Perez-Andreu V; Roberts KG; Harvey RC; Yang W; Cheng C; Pei D; Xu H; Gastier-Foster J; E S; Lim JY; Chen IM; Fan Y; Devidas M; Borowitz MJ; Smith C; Neale G; Burchard EG; Torgerson DG; Klussmann FA; Villagran CR; Winick NJ; Camitta BM; Raetz E; Wood B; Yue F; Carroll WL; Larsen E; Bowman WP; Loh ML; Dean M; Bhojwani D; Pui CH; Evans WE; Relling MV; Hunger SP; Willman CL; Mullighan CG; Yang JJ
Nat Genet; 2013 Dec; 45(12):1494-8. PubMed ID: 24141364
[TBL] [Abstract][Full Text] [Related]
4. Regulatory network of GATA3 in pediatric acute lymphoblastic leukemia.
Hou Q; Liao F; Zhang S; Zhang D; Zhang Y; Zhou X; Xia X; Ye Y; Yang H; Li Z; Wang L; Wang X; Ma Z; Zhu Y; Ouyang L; Wang Y; Zhang H; Yang L; Xu H; Shu Y
Oncotarget; 2017 May; 8(22):36040-36053. PubMed ID: 28415601
[TBL] [Abstract][Full Text] [Related]
5. The biology of Philadelphia chromosome-like ALL.
Roberts KG
Best Pract Res Clin Haematol; 2017 Sep; 30(3):212-221. PubMed ID: 29050694
[TBL] [Abstract][Full Text] [Related]
6. Suppressors and activators of JAK-STAT signaling at diagnosis and relapse of acute lymphoblastic leukemia in Down syndrome.
Schwartzman O; Savino AM; Gombert M; Palmi C; Cario G; Schrappe M; Eckert C; von Stackelberg A; Huang JY; Hameiri-Grossman M; Avigad S; Te Kronnie G; Geron I; Birger Y; Rein A; Zarfati G; Fischer U; Mukamel Z; Stanulla M; Biondi A; Cazzaniga G; Vetere A; Wagner BK; Chen Z; Chen SJ; Tanay A; Borkhardt A; Izraeli S
Proc Natl Acad Sci U S A; 2017 May; 114(20):E4030-E4039. PubMed ID: 28461505
[TBL] [Abstract][Full Text] [Related]
7. A genome-wide association study of susceptibility to acute lymphoblastic leukemia in adolescents and young adults.
Perez-Andreu V; Roberts KG; Xu H; Smith C; Zhang H; Yang W; Harvey RC; Payne-Turner D; Devidas M; Cheng IM; Carroll WL; Heerema NA; Carroll AJ; Raetz EA; Gastier-Foster JM; Marcucci G; Bloomfield CD; Mrózek K; Kohlschmidt J; Stock W; Kornblau SM; Konopleva M; Paietta E; Rowe JM; Luger SM; Tallman MS; Dean M; Burchard EG; Torgerson DG; Yue F; Wang Y; Pui CH; Jeha S; Relling MV; Evans WE; Gerhard DS; Loh ML; Willman CL; Hunger SP; Mullighan CG; Yang JJ
Blood; 2015 Jan; 125(4):680-6. PubMed ID: 25468567
[TBL] [Abstract][Full Text] [Related]
8. Molecular Mechanisms of ARID5B-Mediated Genetic Susceptibility to Acute Lymphoblastic Leukemia.
Zhao X; Qian M; Goodings C; Zhang Y; Yang W; Wang P; Xu B; Tian C; Pui CH; Hunger SP; Raetz EA; Devidas M; Relling MV; Loh ML; Savic D; Li C; Yang JJ
J Natl Cancer Inst; 2022 Sep; 114(9):1287-1295. PubMed ID: 35575404
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of ruxolitinib in acute lymphoblastic leukemia: A systematic review.
Kołodrubiec J; Kozłowska M; Irga-Jaworska N; Sędek Ł; Pastorczak A; Trelińska J; Młynarski W
Leuk Res; 2022 Oct; 121():106925. PubMed ID: 35939887
[TBL] [Abstract][Full Text] [Related]
10.
Al-Zayan NR; Ashour MJ; Abuwarda HN; Sharif FA
Pediatr Hematol Oncol; 2024; 41(2):103-113. PubMed ID: 37578068
[TBL] [Abstract][Full Text] [Related]
11. Inherited genetic susceptibility to acute lymphoblastic leukemia in Down syndrome.
Brown AL; de Smith AJ; Gant VU; Yang W; Scheurer ME; Walsh KM; Chernus JM; Kallsen NA; Peyton SA; Davies GE; Ehli EA; Winick N; Heerema NA; Carroll AJ; Borowitz MJ; Wood BL; Carroll WL; Raetz EA; Feingold E; Devidas M; Barcellos LF; Hansen HM; Morimoto L; Kang AY; Smirnov I; Healy J; Laverdière C; Sinnett D; Taub JW; Birch JM; Thompson P; Spector LG; Pombo-de-Oliveira MS; DeWan AT; Mullighan CG; Hunger SP; Pui CH; Loh ML; Zwick ME; Metayer C; Ma X; Mueller BA; Sherman SL; Wiemels JL; Relling MV; Yang JJ; Lupo PJ; Rabin KR
Blood; 2019 Oct; 134(15):1227-1237. PubMed ID: 31350265
[TBL] [Abstract][Full Text] [Related]
12. GATA3 rs3824662A allele in B-cell acute lymphoblastic leukemia in adults, adolescents and young adults: association with CRLF2 rearrangement and poor prognosis.
Koller PB; Zhang H; Kantarjian H; Jabbour E; Pierce S; Gocho Y; Roberts KG; Yang W; Mullighan CG; Yang J; Konopleva M; Jain N
Am J Hematol; 2021 Mar; 96(3):E71-E74. PubMed ID: 33275800
[No Abstract] [Full Text] [Related]
13. Degradation of Janus kinases in CRLF2-rearranged acute lymphoblastic leukemia.
Chang Y; Min J; Jarusiewicz JA; Actis M; Yu-Chen Bradford S; Mayasundari A; Yang L; Chepyala D; Alcock LJ; Roberts KG; Nithianantham S; Maxwell D; Rowland L; Larsen R; Seth A; Goto H; Imamura T; Akahane K; Hansen BS; Pruett-Miller SM; Paietta EM; Litzow MR; Qu C; Yang JJ; Fischer M; Rankovic Z; Mullighan CG
Blood; 2021 Dec; 138(23):2313-2326. PubMed ID: 34110416
[TBL] [Abstract][Full Text] [Related]
14. Differential expression of MUC4, GPR110 and IL2RA defines two groups of CRLF2-rearranged acute lymphoblastic leukemia patients with distinct secondary lesions.
Sadras T; Heatley SL; Kok CH; Dang P; Galbraith KM; McClure BJ; Muskovic W; Venn NC; Moore S; Osborn M; Revesz T; Moore AS; Hughes TP; Yeung D; Sutton R; White DL
Cancer Lett; 2017 Nov; 408():92-101. PubMed ID: 28866095
[TBL] [Abstract][Full Text] [Related]
15. HOXA9 Cooperates with Activated JAK/STAT Signaling to Drive Leukemia Development.
de Bock CE; Demeyer S; Degryse S; Verbeke D; Sweron B; Gielen O; Vandepoel R; Vicente C; Vanden Bempt M; Dagklis A; Geerdens E; Bornschein S; Gijsbers R; Soulier J; Meijerink JP; Heinäniemi M; Teppo S; Bouvy-Liivrand M; Lohi O; Radaelli E; Cools J
Cancer Discov; 2018 May; 8(5):616-631. PubMed ID: 29496663
[TBL] [Abstract][Full Text] [Related]
16. CRLF2 rearrangement in Ph-like acute lymphoblastic leukemia predicts relative glucocorticoid resistance that is overcome with MEK or Akt inhibition.
Meyer LK; Delgado-Martin C; Maude SL; Shannon KM; Teachey DT; Hermiston ML
PLoS One; 2019; 14(7):e0220026. PubMed ID: 31318944
[TBL] [Abstract][Full Text] [Related]
17. A recombinant antibody fragment directed to the thymic stromal lymphopoietin receptor (CRLF2) efficiently targets pediatric Philadelphia chromosome-like acute lymphoblastic leukemia.
Mohamed SMA; Wohlmann A; Schofield P; Sia KCS; McCalmont H; Savvides SN; Verstraete K; Kavallaris M; Christ D; Friedrich KH; Bayat N; Lock RB
Int J Biol Macromol; 2021 Nov; 190():214-223. PubMed ID: 34481852
[TBL] [Abstract][Full Text] [Related]
18. Variation at 10p12.2 and 10p14 influences risk of childhood B-cell acute lymphoblastic leukemia and phenotype.
Migliorini G; Fiege B; Hosking FJ; Ma Y; Kumar R; Sherborne AL; da Silva Filho MI; Vijayakrishnan J; Koehler R; Thomsen H; Irving JA; Allan JM; Lightfoot T; Roman E; Kinsey SE; Sheridan E; Thompson P; Hoffmann P; Nöthen MM; Mühleisen TW; Eisele L; Zimmermann M; Bartram CR; Schrappe M; Greaves M; Stanulla M; Hemminki K; Houlston RS
Blood; 2013 Nov; 122(19):3298-307. PubMed ID: 23996088
[TBL] [Abstract][Full Text] [Related]
19. Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia.
Mullighan CG; Collins-Underwood JR; Phillips LA; Loudin MG; Liu W; Zhang J; Ma J; Coustan-Smith E; Harvey RC; Willman CL; Mikhail FM; Meyer J; Carroll AJ; Williams RT; Cheng J; Heerema NA; Basso G; Pession A; Pui CH; Raimondi SC; Hunger SP; Downing JR; Carroll WL; Rabin KR
Nat Genet; 2009 Nov; 41(11):1243-6. PubMed ID: 19838194
[TBL] [Abstract][Full Text] [Related]
20. Genome-wide CRISPR-Cas9 screen identifies rationally designed combination therapies for CRLF2-rearranged Ph-like ALL.
Sasaki K; Yamauchi T; Semba Y; Nogami J; Imanaga H; Terasaki T; Nakao F; Akahane K; Inukai T; Verhoeyen E; Akashi K; Maeda T
Blood; 2022 Feb; 139(5):748-760. PubMed ID: 34587248
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
